Published · Last updated
“Peptides for muscle growth” is one of the most common searches that brings UK visitors to this site. The phrase covers several quite different families of molecules, most of which have been studied in animals or in narrow clinical populations rather than in healthy adults. This guide explains what each family is, what the research has reported, and where the evidence stops.
How peptides are studied in muscle research
Muscle hypertrophy research uses peptides in three broad ways: as growth-hormone secretagogues that raise endogenous GH and IGF-1; as direct growth-factor analogues (IGF-1 variants, MGF); and as myostatin pathway inhibitors (follistatin, ACE-031). A fourth group — repair peptides such as BPC-157 and TB-500 — is studied for recovery from muscle injury rather than growth itself.
Growth-hormone secretagogues: GHRP-2, GHRP-6, ipamorelin, hexarelin
Growth-hormone-releasing peptides act on the ghrelin (GHS-R1a) receptor to stimulate pulsatile GH release from the pituitary. In clinical studies GHRP-2 and GHRP-6 produce robust GH increases in both healthy volunteers and GH-deficient patients; ipamorelin is described as more selective, with less effect on cortisol and prolactin; hexarelin is among the most potent but shows tachyphylaxis with repeated use. Whether raised GH translates into meaningful lean-mass gain in healthy adults is far less clear: GH itself increases lean body mass in deficiency states but has repeatedly failed to improve strength in trained athletes in controlled trials.
Related GHRH analogues — sermorelin, CJC-1295 (Mod GRF 1-29) and tesamorelin — act on the GHRH receptor and are often studied in combination with a GHRP. See our tesamorelin guide for a detailed look at the evidence and its limits.
IGF-1 LR3, IGF-1 DES and MGF
Insulin-like growth factor 1 mediates many of GH’s anabolic effects. IGF-1 LR3 is a long-acting analogue with reduced binding to IGF-binding proteins; IGF-1 DES(1-3) is a truncated form with higher local potency. Mechano growth factor (MGF) is a splice variant of IGF-1 expressed in muscle after mechanical loading; the synthetic PEGylated form (PEG-MGF) extends its half-life for research. In cell culture and rodent models these compounds increase satellite-cell activation and myofibre size. Human data are limited to IGF-1 therapy in growth disorders, where side effects include hypoglycaemia and soft-tissue overgrowth.
Myostatin pathway: follistatin and ACE-031
Myostatin (GDF-8) is a negative regulator of muscle mass; animals with loss-of-function mutations show dramatic hypertrophy. Follistatin binds and neutralises myostatin and activin; ACE-031 is a soluble activin receptor IIB decoy. Both produced significant lean-mass increases in animal studies. ACE-031’s human trial in Duchenne muscular dystrophy was halted over safety signals (nosebleeds, telangiectasia), a useful reminder that potent anabolic pathways carry systemic effects.
Repair peptides: BPC-157 and TB-500
These are not growth peptides but are frequently searched alongside them. BPC-157 and TB-500 are studied for tendon, ligament and muscle repair in injury models, where they accelerate functional recovery in rodents. They do not act on GH, IGF-1 or myostatin pathways.
UK context
None of these peptides is a licensed medicine for muscle growth in the UK. Human growth hormone itself is a Class C controlled drug; the peptides above are not controlled but may only be sold for research and may not be supplied for human consumption. See are peptides legal in the UK? for more detail.
Frequently asked questions
Do peptides build muscle?
In animal models, several families increase muscle mass through GH/IGF-1 or myostatin pathways. In healthy humans there are no controlled trials demonstrating meaningful hypertrophy from research peptides.
Are muscle-growth peptides legal in the UK?
Most are not controlled substances and can be sold for research; none is licensed for human use for this purpose, and all are banned in competitive sport.